Back to top

cell-therapy: Archive

Ekta Bagri

Three Genomics Stocks Worth Tracking This Year

Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.

ILMNPositive Net Change BEAMPositive Net Change PACBPositive Net Change WVEPositive Net Change CRSPPositive Net Change SANAPositive Net Change

Zacks Equity Research

BAYRY's 2025 Revival: Will the Momentum Continue in 2026?

BAYRY shares have risen 121.6% in a year as new FDA approvals, pipeline wins and litigation updates fuel a sharp turnaround.

REGNPositive Net Change JNJPositive Net Change BAYRYNegative Net Change

Sundeep Ganoria

3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains

Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.

JNJPositive Net Change MRKPositive Net Change ABBVPositive Net Change

Sundeep Ganoria

BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?

Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.

REGNPositive Net Change BEAMPositive Net Change NTLAPositive Net Change